Entrada reports Phase 1/2 ELEVATE-45-201 Cohort 1 data showing ENTR-601-45 meets safety, tolerability goals in Duchenne muscular dystrophy trial
Bitget2026/10/14 11:03- Entrada Therapeutics released positive topline results already reported from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study in Duchenne muscular dystrophy.
- The initial-dose cohort met the main goal on safety and tolerability, supporting continued dose escalation in later cohorts.
- Early biological activity was observed, though no functional improvement was expected or seen at this stage.
- Enrollment is complete for Cohort 2 at a higher dose, with data scheduled for the first half of 2027.
- The program targets a once-every-six-weeks dosing schedule, positioning it as a lower-frequency alternative to current weekly regimens.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
